```json { "busines Gruppe

Immunosuppressive therapy plays a significant role in treating IGA nephropathy, especially for patients whose condition progresses rapidly or shows signs of severe inflammation. Since the underlying mechanism involves the immune system mistakenly depositing IgA complexes in kidney tissues, controlling this immune activity becomes crucial. Physicians carefully evaluate each patient to determine whether immunosuppression is appropriate, as not all individuals benefit from this approach. Corticosteroids have historically been the most commonly prescribed option, offering anti-inflammatory effects that reduce kidney swelling and prevent ongoing tissue damage. However, steroids must be used thoughtfully to avoid long-term complications such as weight gain, infections, or metabolic disturbances. For patients who do not respond well to steroids or cannot tolerate them, alternative immunosuppressants like cyclophosphamide or mycophenolate mofetil may be considered. These medications work by selectively reducing immune cell activity and minimizing the formation of damaging antibodies. Treatment regimens vary based on clinical presentation, and physicians closely monitor kidney function throughout therapy. Recent advancements have introduced biologic agents that target specific immune pathways, offering more precise control over disease mechanisms. These innovations represent a promising shift toward safer and more effective treatment options. In addition to pharmacological therapy, supportive care remains essential. Patients are advised to maintain healthy lifestyles to reduce renal strain, including proper diet, hydration, and blood pressure management. Regular follow-ups allow early detection of medication-related side effects and adjustments to therapy. While immunosuppression is not required for every case, it remains a vital tool for controlling aggressive forms of IGA nephropathy, helping preserve kidney function and improve quality of life over time.